Q4 and Year-End 2005 PDL BioPharma Earnings Conference Call - Research and Markets Offers a Brief of 'PDL BioPharma' Conference Call.DUBLIN, Ireland -- The PDL See page description language. 1. PDL - Page Description Language. 2. PDL - Program Design Language. 3. PDL - Push Down List. 4. PDL - Dave Lebling, one of the co-authors of Zork. BioPharma (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :PDLI) Corporate Conference Call took place on 27-Feb-06 4:30pm ET. PDLI reported full-year 2005 total operating revenues of $276.9m and 4Q05 total operating revenues of $83.7m. Full-year 2005 GAAP GAAP See: Generally Accepted Accounting Principles GAAP See generally accepted accounting principles (GAAP). net loss was $149.8m or $1.45 per basic and diluted share. The Co. reported 2006 total operating revenue guidance of approx. $405-435m and full-year 2006 non-GAAP earnings guidance based upon adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) A metric used to show a company's profitability, but not its cash flow. EBITDA became popular in the 1980s to show the potential profitability of leveraged buyouts, but has become of approx. $44-54m and full-year 2006 non-GAAP diluted EPS guidance of approx. $0.38-0.47. More information on this Conference Call can be obtained from Research and Markets at http://www.researchandmarkets.com/transcripts/81666 This document provides a non-biased summary of the conference call detailing the key points and the full Q&A session. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion